Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1222 in Postmenopausal Osteoporosis
NCT04435158Phase 1Completed
- Sponsor
- Hengrui
- Start
- Aug 2020
- Primary completion
- Jul 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-1222 in postmenopausal osteoporosis (6 arms), sponsored by Hengrui. Primary endpoint: Number of subjects with adverse events up to 225 days. Started Aug 2020; status: completed.
02
Drugs
SHR-1222
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT04435158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04435158.